Lucid Capital analyst Christopher Liu initiated coverage of Nuvectis Pharma (NVCT) with a Buy rating and $18 price target Nuvectis is a clinical-stage biotechnology company focused on developing targeted small molecule oncology therapies, the analyst tells investors in a research note. The firm believes the company’s lead asset, NXP900, has the potential to treat cancers with high unmet need, particularly heavily pretreated, YES1/Hippo-altered squamous cell carcinomas where there are limited treatment options.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCT:
- Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position
- Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright
- Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year
- Nuvectis Pharma 2.7M share Spot Secondary priced at $5.00
- Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering